Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C009 - Coding and Documentation

Friday, February 16; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate pending changes to the coding and documentation environment to better ensure adherence with latest recommendations.
  • Recognize specific coding conventions pertaining to subject areas like surgery and dermatopathology.
  • Identify operationally significant legal and regulatory constraints that impinge on medical record description and documentation.


CPT coding, appropriate chart documentation, specific issues relevant to dermatopathology and dermatologic surgery, and relevant legal and regulatory implications will be discussed. Coming changes and recent additions will be emphasized. Time will be available for questions from the audience. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.


  • Alam, Murad, MD: Allergan, Inc – C(Fees); Bonti – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Pulse Biosciences – C(Fees); Revance Therapeutics, Inc. – I(Grants/Research Funding);
  • Haas, Ann F., MD: no financial relationships exist with commercial interests.
  • Kaufmann, Mark D., MD: Almirall – C(Fees); BioPharmX – C(Fees); Cutanea Life Sciences – C(Fees); Dermira – C(Fees); IntraDerm Pharmaceuticals – C(Fees); ISDIN – C(Fees); Klara/Goderma, Inc. – C(SO); L'Oreal USA Inc. – C(Fees); La Roche-Posay Laboratorie Pharmaceutique – C(Fees); Menlo Therapeutics – C(Fees); Modernizing Medicine – C(SO); MoleSafe, Inc. – O(Fees), O(ST); Ortho Dermatologics – C(Fees); Pfizer Inc. – C(Fees); Promius Pharma, LLC – C(Fees); SciBASE – C(Fees); Sun Pharmaceutical Industries Ltd. – C(Fees); UCB – C(Fees);
  • Miller, Alexander, MD: no financial relationships exist with commercial interests.
  • Rogers, Howard Wooding, MD: no financial relationships exist with commercial interests.
Friday, February 16
1:05 PM
Dr. Rogers / Modifier 25, and Documentation
1:35 PM
Dr. Kaufmann / RUC Issues and Update
2:05 PM
Dr. Miller / Flaps and Closures
2:35 PM
Dr. Haas / Telehealth Code Development
3:05 PM
Dr. Alam / New CPT Codes: PDT and Laser for Scars
3:35 PM
All faculty / Questions from the Audience
Event Details
  • Date
    Friday, February 16
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 2
  • CME Credits
  • Type
    Practice Management
  • Murad Alam, MD, FAAD
  • Alexander Miller, MD, FAAD
  • Ann F. Haas, MD, FAAD
  • Howard Wooding Rogers, MD, FAAD
  • Mark D. Kaufmann, MD, FAAD - Handout